3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Leukemia, Myeloid, Acute
13
Myelodysplastic Syndromes
9
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Hodgkin Disease
7
Leukemia, Biphenotypic, Acute
5
Burkitt Lymphoma
5
Lymphoma, Non-Hodgkin
4
Hematologic Neoplasms
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Neuroblastoma
3
Neoplasms
3
Leukemia, Myelomonocytic, Chronic
3
Rhabdomyosarcoma
2
Myeloproliferative Disorders
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lymphoma
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia
2
Teratoma
1
Solid Tumors
1
Sarcoma
1
Recurrence
1
Myelodysplastic-Myeloproliferative Diseases
1
Multi-centric Castleman's Disease
1
Malignant mesenchymal tumor
1
Macular dystrophy, corneal type 1
1
Lymphoproliferative Disorders
1
Lymphoma, Large-Cell, Anaplastic
1
Interventions
pasireotide
1
lutetium Lu 177 dotatate
1
lanreotide
1
amino-acid, glucose, and electrolyte solution
1
Sunitinib
1
Octreotide
1
Everolimus
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Gastro-enteropancreatic neuroendocrine tumor
×
Filgrastim
×
90 days
×
Clear all
No trials found.